Change to U-100 insulin does not appear to affect insulin absorption.

Swift, P G; Kennedy, J D; Gerlis, Laurence

doi:10.1136/bmj.286.6370.1015

Cited by 11 publications

(6 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…compared to U-40 when given in a dose of 8 units. In our study as well as in two other studies (Swift, Kennedy and Gerlis 1983;Galloway, Spradlin, Nelson, Wentworth, Davidson and Swarner 1981) no significant differences could be found between identical doses given in different concentrations. Taking all the studies into consideration it seems as if the decreased insulin absorption rate observed with increasing concentration and increasing volume of the injected insulin solution (Binder 1969) is balanced when identical doses of U-40 and of the more concentrated but less voluminous U-100 are given.…”

Section: Discussionsupporting

confidence: 73%

Subcutaneous Absorption of U-40 and U-100 Insulin

Lauritzen¹,

Thorsteinsson²,

Pramming³

et al. 1984

Horm Metab Res

View full text Add to dashboard Cite

Single strength insulin has been recommended in order to reduce dosage errors (Bloom, Keen and Watkins 1981). Most of Europe uses insulin of 40 units/ml (U-40) only, whereas the United States, Canada, Australia, and, recently, Britain have adopted a sole insulin strength of 100 units/ml (U-100). We studied the absorption of identical doses of soluble U-40 and U-100 insulin after a) subcutaneous injection, b) during continuous subcutaneous insulin infusion (SCII), and c) a supplementary meal bolus.

show abstract

Section: Discussionsupporting

confidence: 73%

Subcutaneous Absorption of U-40 and U-100 Insulin

Lauritzen¹,

Thorsteinsson²,

Pramming³

et al. 1984

Horm Metab Res

View full text Add to dashboard Cite

show abstract

“…Injection of insulin aspart resulted in a faster onset of action and a shorter duration of action not only compared to U 100-R, which has already been shown previously (Heinemann et al, 1993), but also in comparison to U40-R. It was expected from a previous analysis of various study results that the In some previous studies injection of U40-R resulted in a more rapid increase in serum insulin concentrations compared to U 100-R (Hildebrandt et al, 1983;Heinemann et al, 1992;Hübinger et al, 1992), which could not be confirmed by others (Galloway et al, 1981;Swift et al, 1983;Lauritzen et al, 1984;Chantelau et al, 1985). Measuring the metabolic activity with the glucose clamp technique, all available studies showed comparable results with U40 and UlOO regular insulin (Heinemann et al, 1992;Hübinger et al, 1992; present study).…”

Section: Discussionmentioning

confidence: 91%

Comparison of the time-action profiles of U40- and U100-regular human insulin and the rapid-acting insulin analogue B28 Asp

Heinemann¹,

Weyer²,

Rave³

et al. 2009

Exp Clin Endocrinol Diabetes

View full text Add to dashboard Cite

It is well known that rapid-acting insulin analogues like insulin aspart (B28Asp) show a faster onset and a shorter duration of action than currently available U100 soluble insulin preparations. Since this effect is mainly due to a lower concentration of slow-absorbable hexamers, the metabolic profile of human insulin in lower concentration (e.g. U40 insulin) might be more similar to that of insulin aspart. Therefore, we compared the pharmacodynamic and pharmacokinetic properties of U40 soluble insulin with insulin aspart (U100) and with U100 human insulin. Eight healthy volunteers received on different study days s.c. injection of insulin aspart and U40 insulin (0.2 U/kg body weight) under euglycaemic clamp conditions (blood glucose 5 mmol/l, basal i.v. insulin infusion 0.15 mU/kg/min). In a second study, U40 and U100 soluble insulin was administered to 9 other volunteers under similar conditions. No significant differences were observed between the summary measures of U40 and U100 insulin. Insulin aspart showed a faster onset and a shorter duration of action than U40 insulin. The metabolic activity of human insulin in concentrations of U40 and U100 is comparable. Subcutaneous injection of the insulin analogue insulin aspart leads to a faster onset and a shorter duration of action even in comparison to U40 insulin.

show abstract

“…In earlier studies, the blood glucose profiles for identical doses of U40 or U100 insulins were found to be similar [5,15]. It should be kept in mind that the day-to-day variance of biological effects of subcutaneously injected insulin is at least as high as the mean differences in this study [3,11].…”

Section: Discussionmentioning

confidence: 91%

“…The absorption rate of subcutaneously injected regular insulin has been shown to correlate inversely with the insulin concentration [1,6,9,10]. Recently, differences in the pharmacokinetics of U40 and U100 formulations of regular insulin have been reported [7], but blood glucose profiles for identical doses of U40 and UI00 insulin were similar [5,15]. Since the absorption profiles and glucoselowering potency may vary due to the different volumes necessary for a given dose of insulin, comparative pharmacokinetic trials are needed in order to test whether clinically relevant differences have to be considered when switching diabetic patients from U40 to U100 insulin.…”

Section: Abstract: Insulin Action-insulin Pharmacokineticsmentioning

confidence: 99%

See 1 more Smart Citation

The pharmacokinetics of two different concentrations of short-acting insulin, intermediate-acting insulin, and an insulin mixture following subcutaneous injection

Hübinger¹,

Weber

Jung

et al. 1992

Clin Investig

View full text Add to dashboard Cite

To compare the pharmacokinetics of two different concentrations, containing either 40 or 100 IU/ml of short-acting human insulin (Velasulin HM), intermediate-acting human insulin (Insulatard HM), or an insulin mixture (25% short-acting insulin, 75% intermediate-acting insulin; Mixtard HM), three randomized, single-blind, crossover trials were performed using the euglycemic clamp technique. Eighteen healthy volunteers received insulin of either formulation subcutaneously in each of the studies (15 IU Velasulin, 20 IU Insulatard, or Mixtard). The blood glucose levels were maintained constant by glucose infusions. In the trial using Velasulin, the two different insulin concentrations were equivalent regarding the total absorption [area under the curve (AUC) of serum insulin: 126 +/- 28 and 123 +/- 35 mU/l x 12 h for U40 and U100 (mean +/- SD)], but not in regard to the rate of absorption (t max 1.3 +/- 0.4 and 2.4 +/- 1.0 h for U40 and U100). In the case of Insulatard, total absorption was not equivalent (AUC 153 +/- 35 and 128 +/- 37 ml/l x 24 h for U40 and U100), but the rate of absorption was equivalent (t max 4.8 +/- 2.9 and 5.3 +/- 4.6 h). In the Mixtard series, total absorption was equivalent (AUC 142 +/- 32 and 128 +/- 22 mU/l x 24 h), but the rate of absorption was not (t max 2.2 +/- 0.9 and 3.2 +/- 4.2 h for U40 and U100). The glucose requirement was not equivalent in each of the three series.(ABSTRACT TRUNCATED AT 250 WORDS)

show abstract

Change to U-100 insulin does not appear to affect insulin absorption.

Cited by 11 publications

References 2 publications

Subcutaneous Absorption of U-40 and U-100 Insulin

Subcutaneous Absorption of U-40 and U-100 Insulin

Comparison of the time-action profiles of U40- and U100-regular human insulin and the rapid-acting insulin analogue B28 Asp

The pharmacokinetics of two different concentrations of short-acting insulin, intermediate-acting insulin, and an insulin mixture following subcutaneous injection

Contact Info

Product

Resources

About